Primary LymphedemaNCT01748604
Physical Therapies in the Decongestive Treatment of Lymphedema
A study testing Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC) and multilayer, multicomponent bandages (MB) in people with Primary Lymphedema and Secondary Lymphedema, run by Isabel Forner-Cordero, MD, PhD. at 1 site in Spain.
Trial summary
The purpose of this multicenter randomised controlled study is to determine whether manual lymphatic drainage (MLD) brings any benefit when added to intermittent pneumatic compression (IPC) plus multilayer, multicomponent bandages (MB) in the decongestive lymphatic therapy (DLT) in patients with lymphedema Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Primary Lymphedema, Secondary Lymphedema
- What is being tested?
- Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC) and multilayer, multicomponent bandages (MB)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 194 participants
- Where
- 1 siteSpain
- Study dates
- Feb 2004to Jun 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- primary or secondary lymphedema,
- lymphedema stages II or III
- affecting unilateral upper or lower limb
- Excess volume (EV) > 10%
Who cannot join
- malignancy or active neoplasm disease or lack of information about it.
- active lymphangitis
- known contraindications for Decongestive Lymphatic Therapy (DLT): renal insufficiency, uncontrolled hypertension, cardiac disease and venous thrombosis.
- a course of DLT during last year.
- anything that could alter the patient's capability to consent truly to participate in this study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Physical Therapies in the Decongestive Treatment of Lymphedema: A Multicenter, Randomized, Controlled Study.
The purpose of this multicenter randomised controlled study is to determine whether manual lymphatic drainage (MLD) brings any benefit when added to intermittent pneumatic compression (IPC) plus multilayer, multicomponent bandages (MB) in the decongestive lymphatic therapy (DLT) in patients with lymphedema
Read the detailed description
Study Design: the study was a multicenter, randomized controlled study conducted at three university hospitals in Spain. Potential subjects were identified at Rehabilitation Department where physicians were responsible for screening subjects for eligibility and enrolling into the study.
Patients that fulfilled the inclusion criteria and signed up the informed consent were stratified within 2 stratums, upper and lower limb lymphedema, and then were randomized to one of the three treatment groups.
The type of randomization was a total randomization with ratio 1:1:1 and the method used to generate the random allocation sequence was a computer-generated random numbers table. Adequate randomization includes calling a central office once eligibility has been determined.
The physicians that assessed the outcome and the statistic who analyzed de data were blinded to the subjects' treatment assignment.
The study was approved by the Research Ethics Committee of the University Hospital La Fe. It was conducted according to the ethical principles laid down in the declaration of Helsinki (52nd World Medical Association General Assembly, Edinburgh, Scotland, October 2000) and the rules of best clinical practice.
Treatment Regimens: Patients were randomized to one of the following treatment groups:
- Group A or control group: Manual Lymphatic Drainage (MLD) with Földi's technique by an expert therapist during 45 minutes; intermittent pneumatic compression (IPC) with multicompartmental pump between 50 to 80 mmHg during 30 minutes, followed by multilayer, multicomponent bandages (MB) until next day.
- Group B: Pneumatic massage with Lymphapress-Plus(TM) device that was lent during the duration of the study during 20 minutes, and was supposed to open the proximal lymphatics at the root of the limb; IPC (50 to 80 mmHg during 30 minutes), followed by MB until next day.
- Group C: IPC (50 to 80 mmHg during 30 minutes) followed by MB until next day.
All patients were planned to receive 20 sessions of treatment (5 per week in consecutive days during 4 consecutive weeks) and were trained in skin care and daily exercises.
After DLT, garments were prescribed and their adaptation was checked to warrant the maintenance of the results. The garments were flat knitted, custom made, generally class 2 (18-21 mmHg) for upper limb, and class 3 (36-46 mmHg) for lower limb.
Sample Size and Statistical analyses: This trial compares the efficacy of two treatment modalities without MLD (experimental group B and C) with a standard trimodal therapy (control group A). The expected effect size in percentage reduction in excess volume (PREV), primary end point, for the control group (MLD+IPC+MB) was defined from the review of literature and was 50 to 70% (mean 60%) with a standard deviation of 20 to 30 (mean 25). Our hypothesis was that there are no differences between experimental and standard treatment.
The required sample size for the study was 177 patients or 59 subjects per group to detect differences greater than or equal 15% in the percentage reduction in excess volume (PREV) between control and experimental groups, if exists; considering differences less than 15% as not clinically significant. It was based on an alpha error of 5% and a power of 90%. We estimated a drop-out rate of 10%. Therefore, 17 patients were added, resulting in a sample size of 194 subjects.
To compare baseline characteristics between three groups we use two-way ANOVA test for continuous variable and Pearson's chi2 for categorical data, to detect potential confounding factors. Outcome data were analyzed utilizing a two-way ANOVA test to assess differences between treatment groups with a 5% level of significance (p≤0.05) and two-tailed tests.
An exploratory subgroup analysis was made to identify factors associated with response (PREV). Factors for initial screening were identified by univariate linear regression model with a p value <0.1. In order to determine the independent predictive factors, a multivariate linear regression analysis was applied.
- Conditions
- Primary Lymphedema, Secondary Lymphedema
- Being tested
- Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC), multilayer, multicomponent bandages (MB), Lymphapress-Plus(TM) device (LPD)
- Keywords
- Lymphedema, Physical Therapies, Randomized controlled study, Decongestive lymphatic therapy, Manual lymph drainage, Intermittent pneumatic compression, Multilayer bandages
- Medical subject headings
- Lymphedema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Manual Lymphatic Drainage (MLD)Other
MLD with Földi's technique by an expert therapist during 45 minutes
Generic intermittent pneumatic compression Device (IPC)Device
Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
multilayer, multicomponent bandages (MB)Other
multilayer, multicomponent bandages (MB) until next day.
Lymphapress-Plus(TM) device (LPD)Device
Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Standard trimodality therapy with MLD | Active comparator | Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day. Receives: Other: Manual Lymphatic Drainage (MLD); Device: Generic intermittent pneumatic compression Device (IPC); Other: multilayer, multicomponent bandages (MB) |
| Trimodality therapy with LPD | Experimental | Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day Receives: Device: Generic intermittent pneumatic compression Device (IPC); Other: multilayer, multicomponent bandages (MB); Device: Lymphapress-Plus(TM) device (LPD) |
| Bimodality therapy without MLD | Experimental | intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day. Receives: Device: Generic intermittent pneumatic compression Device (IPC); Other: multilayer, multicomponent bandages (MB) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage reduction in Excess Volume (PREV)
It is obtained with the following formula: [(Initial EV - Final EV)/ Initial EV] x 100; where Excess Volume (EV) is the difference between Lymphedematous (VL) and Healthy limb volume (VH).
Volumes were calculated with tape perimeter measurements (C) taken from the dorsum of the hand (C1) and repeated for every 4 cm proximally until the axilla (Cn), using Kuhnke formula, as the disk model is considered the method of choice in clinical practice.
We assessed the change from baseline in PREV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.
Measured: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT
Secondary outcomes (1)
the Percentage of Volume reduction (PRV)
it was calculated with the following formula: [(Initial VL - Final VL)/ Initial VL] x 100.
We assessed the change from baseline in PRV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.
Measured: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2012 (estimated)
- Study startFeb 2004
- Primary completionJan 2010
- Study completionJun 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Primary LymphedemaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 194 participants (actual)
Sponsor and investigators
- Lead sponsor
- Isabel Forner-Cordero, MD, PhD.
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Isabel Forner-Cordero, MD, PhD., Hospital Universitario La Fe
- Investigators
- Isabel I Forner-Cordero, MD, Phd, Study director, University Hospital La FeJose J Muñoz-Langa, MD, Phd, Principal investigator, University Hospital Dr Peset
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01748604
- Sponsor's protocol ID
- HULaFe-LYMPHEDEMA-04
- Status last verified
- Dec 2012
- First submitted
- 6 Dec 2012
- Last updated
- 18 Dec 2012
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. Lymphology. 1998 Jun;31(2):56-64.
PubMed 9664269McNeely ML, Magee DJ, Lees AW, Bagnall KM, Haykowsky M, Hanson J. The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat. 2004 Jul;86(2):95-106. doi: 10.1023/B:BREA.0000032978.67677.9f.
PubMed 15319562Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003141. doi: 10.1002/14651858.CD003141.pub2.
PubMed 15495042
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physical Therapies in the Decongestive Treatment of Lymphedema: A Multicenter, Randomized, Controlled Study.
- ClinicalTrials.gov ID
- NCT01748604
- Acronym / sponsor ID
- HULaFe-LYMPHEDEMA-04
- Conditions
- Primary Lymphedema, Secondary Lymphedema
- Keywords
- Lymphedema, Physical Therapies, Randomized controlled study, Decongestive lymphatic therapy, Manual lymph drainage, Intermittent pneumatic compression, Multilayer bandages
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 194 participants (actual)
- Lead sponsor
- Isabel Forner-Cordero, MD, PhD.University, hospital or other
- Study start
- Feb 2004
- Primary completion
- Jan 2010 (actual)
- Study completion
- Jun 2012 (actual)
- First posted
- 12 Dec 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this multicenter randomised controlled study is to determine whether manual lymphatic drainage (MLD) brings any benefit when added to intermittent pneumatic compression (IPC) plus multilayer, multicomponent bandages (MB) in the decongestive lymphatic therapy (DLT) in patients with lymphedema
Detailed description
Study Design: the study was a multicenter, randomized controlled study conducted at three university hospitals in Spain. Potential subjects were identified at Rehabilitation Department where physicians were responsible for screening subjects for eligibility and enrolling into the study.
Patients that fulfilled the inclusion criteria and signed up the informed consent were stratified within 2 stratums, upper and lower limb lymphedema, and then were randomized to one of the three treatment groups.
The type of randomization was a total randomization with ratio 1:1:1 and the method used to generate the random allocation sequence was a computer-generated random numbers table. Adequate randomization includes calling a central office once eligibility has been determined.
The physicians that assessed the outcome and the statistic who analyzed de data were blinded to the subjects' treatment assignment.
The study was approved by the Research Ethics Committee of the University Hospital La Fe. It was conducted according to the ethical principles laid down in the declaration of Helsinki (52nd World Medical Association General Assembly, Edinburgh, Scotland, October 2000) and the rules of best clinical practice.
Treatment Regimens: Patients were randomized to one of the following treatment groups:
- Group A or control group: Manual Lymphatic Drainage (MLD) with Földi's technique by an expert therapist during 45 minutes; intermittent pneumatic compression (IPC) with multicompartmental pump between 50 to 80 mmHg during 30 minutes, followed by multilayer, multicomponent bandages (MB) until next day.
- Group B: Pneumatic massage with Lymphapress-Plus(TM) device that was lent during the duration of the study during 20 minutes, and was supposed to open the proximal lymphatics at the root of the limb; IPC (50 to 80 mmHg during 30 minutes), followed by MB until next day.
- Group C: IPC (50 to 80 mmHg during 30 minutes) followed by MB until next day.
All patients were planned to receive 20 sessions of treatment (5 per week in consecutive days during 4 consecutive weeks) and were trained in skin care and daily exercises.
After DLT, garments were prescribed and their adaptation was checked to warrant the maintenance of the results. The garments were flat knitted, custom made, generally class 2 (18-21 mmHg) for upper limb, and class 3 (36-46 mmHg) for lower limb.
Sample Size and Statistical analyses: This trial compares the efficacy of two treatment modalities without MLD (experimental group B and C) with a standard trimodal therapy (control group A). The expected effect size in percentage reduction in excess volume (PREV), primary end point, for the control group (MLD+IPC+MB) was defined from the review of literature and was 50 to 70% (mean 60%) with a standard deviation of 20 to 30 (mean 25). Our hypothesis was that there are no differences between experimental and standard treatment.
The required sample size for the study was 177 patients or 59 subjects per group to detect differences greater than or equal 15% in the percentage reduction in excess volume (PREV) between control and experimental groups, if exists; considering differences less than 15% as not clinically significant. It was based on an alpha error of 5% and a power of 90%. We estimated a drop-out rate of 10%. Therefore, 17 patients were added, resulting in a sample size of 194 subjects.
To compare baseline characteristics between three groups we use two-way ANOVA test for continuous variable and Pearson's chi2 for categorical data, to detect potential confounding factors. Outcome data were analyzed utilizing a two-way ANOVA test to assess differences between treatment groups with a 5% level of significance (p≤0.05) and two-tailed tests.
An exploratory subgroup analysis was made to identify factors associated with response (PREV). Factors for initial screening were identified by univariate linear regression model with a p value <0.1. In order to determine the independent predictive factors, a multivariate linear regression analysis was applied.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Standard trimodality therapy with MLD | Active comparator | Other: Manual Lymphatic Drainage (MLD), Device: Generic intermittent pneumatic compression Device (IPC), Other: multilayer, multicomponent bandages (MB)Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day. |
| Trimodality therapy with LPD | Experimental | Device: Generic intermittent pneumatic compression Device (IPC), Other: multilayer, multicomponent bandages (MB), Device: Lymphapress-Plus(TM) device (LPD)Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day |
| Bimodality therapy without MLD | Experimental | Device: Generic intermittent pneumatic compression Device (IPC), Other: multilayer, multicomponent bandages (MB)intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- primary or secondary lymphedema,
- lymphedema stages II or III
- affecting unilateral upper or lower limb
- Excess volume (EV) > 10%
Key exclusion criteria (5 listed)
- malignancy or active neoplasm disease or lack of information about it.
- active lymphangitis
- known contraindications for Decongestive Lymphatic Therapy (DLT): renal insufficiency, uncontrolled hypertension, cardiac disease and venous thrombosis.
- a course of DLT during last year.
- anything that could alter the patient's capability to consent truly to participate in this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Manual Lymphatic Drainage (MLD)MLD with Földi's technique by an expert therapist during 45 minutes | Other | Standard trimodality therapy with MLD |
| Generic intermittent pneumatic compression Device (IPC)Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes. | Device | Bimodality therapy without MLD, Standard trimodality therapy with MLD, Trimodality therapy with LPD |
| multilayer, multicomponent bandages (MB)multilayer, multicomponent bandages (MB) until next day. | Other | Bimodality therapy without MLD, Standard trimodality therapy with MLD, Trimodality therapy with LPD |
| Lymphapress-Plus(TM) device (LPD)Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes. | Device | Trimodality therapy with LPD |
Primary outcome
Percentage reduction in Excess Volume (PREV)
Time frame: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT
It is obtained with the following formula: [(Initial EV - Final EV)/ Initial EV] x 100; where Excess Volume (EV) is the difference between Lymphedematous (VL) and Healthy limb volume (VH). Volumes were calculated with tape perimeter measurements (C) taken from the dorsum of the hand (C1) and repeated for every 4 cm proximally until the axilla (Cn), using Kuhnke formula, as the disk model is considered the method of choice in clinical practice. We assessed the change from baseline in PREV during Decongestive Lymphedema Treatment (DLT)and during 12 months of follow-up after DLT.
1 secondary outcome
the Percentage of Volume reduction (PRV)
Time frame: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2012.
- Background: PubMed 9664269Johansson K, Lie E, Ekdahl C, Lindfeldt J. A randomized study comparing manual lymph drainage with sequential pneumatic compression for treatment of postoperative arm lymphedema. Lymphology. 1998 Jun;31(2):56-64.
- Background: PubMed 15319562McNeely ML, Magee DJ, Lees AW, Bagnall KM, Haykowsky M, Hanson J. The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat. 2004 Jul;86(2):95-106. doi: 10.1023/B:BREA.0000032978.67677.9f.
- Background: PubMed 15495042Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003141. doi: 10.1002/14651858.CD003141.pub2.
Related trials for Primary Lymphedema
Not yet recruiting
Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors
Breast Neoplasm Malignant Primary, Lymphedema Arm
Active, not recruiting
The Effectiveness of Lymphatic Bypass Supermicrosurgery
Breast Cancer Related Lymphedema, Lymphedema Arm
Not yet recruiting
Inelastic Compression Use in Primary Lymphedema
Lymphedema Primary
RecruitingObservational study
Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
Vascular Anomaly, Osler Rendu Disease
Not yet recruitingObservational study
Biological Profile of Primary and Secondary Lymphedema: Inflammatory, Endothelial, Metabolic, Lymphatic, and Fibrotic Markers
Primary Lymphedema, Secondary Lymphedema
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Isabel I Forner-Cordero, MD, Phd study director
University Hospital La Fe
Jose J Muñoz-Langa, MD, Phd principal investigator
University Hospital Dr Peset
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Manual Lymphatic Drainage (MLD), Generic intermittent pneumatic compression Device (IPC) and multilayer, multicomponent bandages (MB) in people with Primary Lymphedema and Secondary Lymphedema, run by Isabel Forner-Cordero, MD, PhD. at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage reduction in Excess Volume (PREV) (time frame: at 10 sessions of DLT (2 weeks), at 20 sessions of DLT (4 weeks) and at 1, 6 and 12 months after the end of DLT). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01748604, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2012.